Volume 133, Issue 13



March 28, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Endothelial protein C receptor supports stem cell engraftment and expansion. See the article by Kohlscheen et al.

Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation
In a Plenary Paper, the authors examine activation and effector functions of normal and FcγRIIIB (CD16B)–negative neutrophils. Their work reveals that normal neutrophils also express FcγRIIIA (CD16A) and that the two receptors on neutrophils mediate distinctly different effector functions for processing antibody-opsonized substrates.

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
The investigators present positive results from a randomized study (HOVON-97) showing that disease-free survival (DFS) in older patients with acute myeloid leukemia (AML) is improved by azacitidine compared with postremission observation.

Endothelial protein C receptor supports hematopoietic stem cell engraftment and expansion in Mpl-deficient mice
This paper addresses the role of Mpl receptor activity in the function of long-term hematopoietic stem cells in the context of transplantation and identifies the endothelial protein C receptor as a downstream mediator of Mpl signaling.

MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans
This study shows that MAA868, a novel humanized monoclonal antibody that locks factor XIa (FXIa) in a zymogenlike state, produces long-lasting antithrombotic effects without disrupting hemostasis. These findings have the potential to change practice by offering safer anticoagulant therapy to treat thrombosis.

FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias
FLT3-ITD mutations are common in acute promyelocytic leukemia. This study begins to unravel how the mutation-activated FLT3 receptor impedes the effects of all-trans retinoic acid and how arsenic trioxide counters this resistance.

Review Series: Single-Cell Technology Meets Hematology
In this issue of Blood, we present a series of 5 reviews and 1 editorial covering the revolutionary impact of single-cell technologies on our understanding of normal and disrupted hematopoiesis. The authors discuss emerging views about hematopoiesis at the single-cell level and compare these observations with the classic hierarchical model under conditions of normal and abnormal hematopoiesis.

The articles in this review series include the following:

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.